**Name of Journal:** ***World Journal of*** ***Gastroenterology***

**Manuscript NO: 42268**

**Manuscript Type:** **ORIGINAL ARTICLE**

*Basic Study*

Identification and prediction of novel non-coding and coding RNA-associated competing endogenous RNA networks in colorectal cancer

Liang Y *et al.* Prediction of CRC ceRNA networks

Yu Liang, Cheng Zhang, Ming-hui Ma, Dong-qiu Dai

**Yu Liang, Cheng Zhang, Ming-hui Ma, Dong-qiu Dai,** Department of Gastrointestinal Surgery, the Fourth Affiliated Hospital of China Medical University, Shenyang 110032, Liaoning Province, China

**ORCID number:** Yu Liang (0000-0001-9136-7139);Cheng Zhang (0000-0001-5317-8775); Ming-Hui Ma (0000-0002-2566-0932); Dong-Qiu Dai (0000-0002-1154-3276).

**Author contributions:** Dai DQ conducted the study; Liang Y, Zhang C, and Ma MH applied the experiments on TCGA project; Liang Y wrote the manuscript.

**Supported by** theNational Natural Science Foundation of China, No. 30572162; and Natural Science Foundation of Liaoning Province, No. 201602817.

**Conflict-of-interest statement:** The authors declare that there is no conflict of interest related to this study.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Corresponding author: Dong-Qiu Dai, PhD, Chief Doctor, Professor, Surgical Oncologist,** Department of Gastrointestinal Surgery, the Fourth Affiliated Hospital of China Medical University, 4 Chongshan Road, Shenyang 110032, Liaoning province, China. daidq63@163.com

**Telephone:** +86-24-62043110

**Fax:** +86-24-62043110

**Received:** September 17, 2018

**Peer-review started:** September 17, 2018

**First decision:** October 14, 2018

**Revised:** October 18, 2018

**Accepted:** November 9, 2018

**Article in press:** November 9, 2018

**Published online:** December 14, 2018

**Abstract**

***AIM***

To identify and predict the competing endogenous RNA (ceRNA) networks in colorectal cancer (CRC) by bioinformatics analysis.

***METHODS***

In the present study, we obtained CRC tissue and normal tissue gene expression profiles from The Cancer Genome Atlas project. Differentially expressed (DE) genes (DEGs) were identified. Then, upregulated and downregulated miRNA-centered ceRNA networks were constructed by analyzing the DEGs using multiple bioinformatics approaches. DEmRNAs in the ceRNA networks were identified in Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways using KEGG Orthology Based Annotation System 3.0. The interactions between proteins were analyzed using the STRING database. Kaplan–Meier survival analysis was conducted for DEGs and real time quantitative polymerase chain reaction (RT-qPCR) was also performed to validate the prognosis-associated lncRNAs in CRC cell lines.

***RESULTS***

Eighty-one DElncRNAs, 20 DEmiRNAs, and 54 DEmRNAs were identified to construct the ceRNA networks of CRC. The KEGG pathway analysis indicated that nine out of top ten pathways were related with cancer and the most significant pathway was “colorectal cancer”. Kaplan–Meier survival analysis showed that the overall survival was positively associated with five DEGs (IGF2-AS, POU6F2-AS2, hsa-mir-32, hsa-mir-141, and SERPINE1) and it was negatively related to three DEGs (LINC00488, hsa-mir-375, and PHLPP2). Based on the STRING protein database, it was found that SERPINE1 and PHLPP2 interact with AKT1. Besides, SERPINE1 can interact with VEGFA, VTN, TGFB1, PLAU, PLAUR, PLG, and PLAT. PHLPP2 can interact with AKT2 and AKT3. RT-qPCR revealed that the expression of IGF2-AS, POU6F2-AS2, and LINC00488 in CRC cell lines was consistent with the *in silico* results.

***CONCLUSION***

CeRNA networks play an important role in CRC. Multiple DEGs are related with clinical prognosis, suggesting that they may be potential targets in tumor diagnosis and treatment.

**Key words:** Colorectal cancer; LncRNA; miRNA; Overall survival; Competing endogenous RNA; Bioinformatics analysis

**© The Author(s) 2018.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** We acquired high-throughput data from The Cancer Genome Atlas database and constructed the competing endogenous RNA (ceRNA) networks of colorectal cancer by bioinformatics analysis, which included 81 differentially expressed (DE)lncRNAs, 20 DEmiRNAs, and 54 DEmRNAs. Furthermore, 3 lncRNAs, 3 miRNAs, and 2 mRNAs were found associated with overall survival. Our study revealed that ceRNA networks are important in colorectal cancer and the prognosis-related genes worth exploring further.

Liang Y, Zhang C, Ma MH, Dai DQ. Identification and prediction of novel non-coding and coding RNA-associated competing endogenous RNA networks in colorectal cancer. *World J Gastroenterol* 2018; 24(46): 5259-5270

URL: https://www.wjgnet.com/1007-9327/full/v24/i46/5259.htm

DOI: https://dx.doi.org/10.3748/wjg.v24.i46.5259

Introduction

Colorectal cancer (CRC) is one of the most common digestive malignancies in the world[1]. With the development of new technology in CRC diagnosis and treatment, the prognosis of patients with early detection has been improved. However, the overall 5-year survival rate in advanced cases remains poor[2]. In the USA, CRC was the fourth most common malignant tumor, with 135,430 new cases and 50,260 deaths in 2017[3]. Therefore, specific CRC biomarkers and therapeutic pathways are in great need to improve the prognosis for patients.

Non-coding RNAs, including microRNAs (miRNAs) and long-noncoding RNAs (lncRNAs), can regulate oncogene and tumor suppressor gene expression in multiple ways[4,5]. MiRNAs are 20-22 nucleotides long and regulate genes post-transcriptionally by directly binding mRNAs[6]. LncRNAs are defined as transcripts that range from 200 nucleotides to multiple kilobases in length[7]. Recent research has focused on these lncRNAs, which function as competing endogenous RNAs (ceRNAs) to regulate gene expression by sponging miRNAs through shared miRNA response elements[8].

In the last few years, with the development of gene-sequencing technology, dysregulation of lncRNAs has been revealed in diverse malignancies. Studies have utilized bioinformatics tools to predict the target genes of novel lncRNAs, and molecular biology techniques including real time quantitative polymerase chain reaction (RT-qPCR), silencing technique, and luciferase reporter gene assays, among others, to validate *in silico* predictions. In CRC, the lncRNA UICLM acts as a ceRNA for hsa-mir-215 to upregulate ZEB2 expression and promote CRC progression[9]. Additionally, the lncRNA HNF1A-AS1 functions as an oncogene in the metastasis of CRC by modulating the hsa-mir-34/p53 axis[10]. Finally, the lncRNA CASC2 plays a role as a tumor suppressor gene by sponging hsa-mir-18a[11].

The lncRNA/miRNA/mRNA axis is regarded as an important mechanism in tumor progression and metastasis[12]. However, studies of ceRNA networks of novel coding and noncoding RNAs in CRC in large cohorts have not been performed. In our study, we obtained malignant and normal tissue expression profiles from The Cancer Genome Atlas (TCGA, http://cancergenome.nih.gov) project[13]. CeRNA networks were constructed including differentially expressed mRNAs (DEmRNAs), differentially expressed lncRNAs (DElncRNAs), and differentially expressed miRNAs (DEmiRNAs), which were based on the miRcode (http://www.mircode.org/)[14], miRTarBas (http://mirtarbase.mbc.nctu.edu.tw/php/)[15], TargetScan (http://www.targetscan.org/), and miRDB (http://www.mirdb.org/) databases[16]. Kaplan-Meier survival curve analysis was performed to identify differentially expressed genes (DEGs) that are associated with overall survival.

MATERIALS AND METHODS

***Sample collection***

We downloaded CRC transcriptome profiles from TCGA through the Genomic Data Commons (GDC) Data Transfer Tool 1.3.0[13]. The public data included the tissue expression profiles (derived by RNA-seq) of 644 CRC tissues and 51 normal tissues (level 3) and 619 CRC and 11 normal tissue expression profiles (level 3) derived by miRNA-seq. According to the publication guidelines (2015) provided by TCGA (https://cancergenome.nih.gov/publications/publicationguidelines), our study does not require the approval of an ethics committee.

***Identification of DEGs***

We analyzed the RNA-seq data by merging it to an RNA matrix with PERL software. Then, we converted the gene ID to gene name according to Ensembl (Homo sapiens) (http://asia.ensembl.org/index.html). The miRNA-seq data were analyzed using the same method. DEmRNAs, DElncRNAs, and DEmiRNAs were identified with the edgeR package in R with a threshold log2 fold change (FC) > 2.0 and *P* < 0.01. Heat maps of DEGs were constructed using the gplots package in R.

***Functional analysis and ceRNA network construction***

Next, we constructed ceRNA networks that were mapped by identifying DEGs to an established co-expression database (miRcode, miRTarBase, TargetScan, and miRDB). LncRNA-miRNA-mRNA reactions were split into lncRNA–miRNA and miRNA–mRNA interactions. LncRNA-miRNA interactions were predicted by comparing DElncRNAs and DEmiRNAs to the miRcode database. DEmRNAs regulating genes of DEmiRNAs were identified by intersecting the predicted results between miRTarBase, TargetScan, and the miRDB databases. According to the ceRNA hypothesis[12], miRNAs negatively regulate mRNA expression and lncRNAs act as ceRNAs to limit miRNA function by sponging them. The networks were visualized and mapped using Cytoscape v3.5.1[17].

To explore the function of the DEGs in the ceRNA networks in tumorigenesis and metastasis, KEGG pathways[18] were analyzed using KOBAS (http://kobas.cbi.pku.edu.cn/), which is a web server that annotates an input set of genes with pathways based on human disease databases[19]. Then, we utilized STRING protein database v10.5 (<http://string-db.org/)> to analyze the protein-protein interactions of the DEGs.

***Association analysis between DEGs and CRC patient survival***

We selected CRC adenocarcinoma and adjacent normal tissue expression data and clinical information from TCGA project. None of the patients received preoperative treatment. Kaplan–Meier survival analysis and the log-rank test were performed for DEGs in the ceRNA networks. *P* < 0.05 was regarded as statistically significant.

***Cell lines and cell culture***

The CRC cell lines HT29, LoVo, and SW480, along with the normal intestinal epithelial cell line NCM460, were purchased from the Institute of Biochemistry and Cell Biology at the Chinese Academy of Sciences, Shanghai, China. The cell lines were cultured in RPMI 1640 medium (HyClone, Logan, UT, United States) supplemented with 10% fetal bovine serum (Gibco, Grand Island, NY, United States), 100 U/mL penicillin, and 100 μg/mL streptomycin. All cells were maintained in an incubator with a humidified atmosphere of 95% air and 5% CO2 at 37 °C.

***DElncRNA detection***

Total RNA was isolated from the cells using Trizol reagent (Invitrogen, Carlsbad, CA, United States). The quality and concentration of isolated RNA were detected with a NanoDrop 2000 spectrophotometer. Total RNA (800 ng) was converted to cDNA by using the PrimeScript TM RT reagent Kit (Takara, Otsu, Shiga, Japan). The Kit contained gDNA Eraser which could remove genomic DNA. We utilized LightCycler96 (Roche Diagnostic, Basel, Switzerland) to perform RT-qPCR using SYBR Green (Takara). The two-step amplification reaction was as follows: 95 °C for 30 s for preincubation, then 45 cycles of 95 °C for 10 s and 60 °C for 30 s. GAPDH expression was used as an endogenous control. Quantitative analysis was calculated using the 2-ΔΔCt method[20]. Primers were designed as follows: POU6F2-AS2 forward, 5ʹ-ACAGCAGTGCCAGAAGGAGTATTG-3ʹ and reverse, 5ʹ-GCAGACCTGAGCTTGTGAGTGAC-3ʹ; LINC00488 forward, 5ʹ-GAGCAGCAAGAATGAGAGCAGAGG-3ʹ and reverse, 5ʹ-GAATCTGAGGAAGCACCGTGAACC-3ʹ; IGF2-AS forward, 5ʹ-TCCACACCAGACAGCACAGACC-3ʹ and reverse, 5ʹ-TCCGTGGTTGGCTCCAGGTG-3ʹ; GAPDH forward, 5ʹ-AGCCACATCGCTCAGACAC-3ʹ and reverse, 5ʹ-GCCCAATACGACCAAATCC-3ʹ.

***Statistical analysis***

All data were analyzed using SPSS 20.0 (Chicago, IL, United States). Student’s *t*-test was performed for CRC cell lines and normal intestinal epithelial cell line comparisons. Differences with *P* < 0.05 were regarded as statistically significant. All experiments were repeated three times.

RESULTS

***Identification of DEGs in CRC***

We identified DElncRNAs and DEmRNAs between 644 CRC and 51 normal tissue expression profiles from TCGA. As a result, we identified 1043 DElncRNAs, 2146 DEmRNAs, and 276 DEmiRNAs using the edgeR package in R. There were 768 up-regulated and 275 down-regulated DEGs among the DElncRNAs, and 1198 up-regulated and 948 down-regulated DEGs in the DEmRNAs. Using the same method, 180 up-regulated and 96 down-regulated DEmiRNAs were obtained by comparing 619 CRC and 11 normal tissue expression profiles. Moreover, we constructed heat maps of the top DEGs (log2 FC > 5, *P* < 0.01) in each category using R (Figures 1-3).

***Construction of ceRNA networks***

To construct the ceRNA networks, we predicted the interactions among DEGs using online bioinformatics tools. We utilized miRcode to predict the interactions between DElncRNAs and DEmiRNAs and we also predicted DEmRNAs targeted by the DEmiRNAs by intersecting the predictions of miRTarBase, TargetScan, and miRDB (Figure 4). Ultimately, 81 DElncRNAs, 20 DEmiRNAs, and 54 DEmRNAs were identified to construct the ceRNA networks of CRC using Cytoscape (Figure 5). The interactions among DEGs are shown in Tables 1 and 2.

***Functional analysis of DEmRNAs in ceRNA networks***

To better reveal the function of ceRNA networks in CRC, we subjected the 54 DEmRNAs in the ceRNA networks to Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis using KEGG Orthology Based Annotation System (KOBAS) 3.0, and the top ten KEGG pathways are shown in Table 3. There were nine pathways related to cancer, including “Colorectal cancer”, “p53 signaling pathway”, “Chronic myeloid leukemia”, “Proteoglycans in cancer”, “miRNAs in cancer”, “Thyroid cancer”, “Transcriptional misregulation in cancer”, “Pathways in cancer”, and “Wnt signaling pathway”. These results indicate that ceRNA networks play important roles in the carcinogenesis and progression of CRC.

***DEGs related with prognosis of CRC patients***

We preformed Kaplan–Meier curve analysis to identify the DEGs in the ceRNA networks that are related to overall survival. The results showed that 3 DElncRNAs (IGF2-AS, POU6F2-AS2, and LINC00488), 3 DEmiRNAs (hsa-mir-32, hsa-mir-141, and hsa-mir-375), and 2 DEmRNAs (PHLPP2 and SERPINE1) were associated with the clinical prognosis of patients. The Kaplan–Meier curves showed that the lncRNAs IGF2-AS and POU6F2-AS2, as well as hsa-mir-32, hsa-mir-141, and serpin peptidase inhibitor, clade E member 1 (SERPINE1) were negatively correlated with overall survival, whereas LINC00488, hsa-mir-375, and PH domain and leucine rich repeat protein phosphatase 2 (PHLPP2) were positively correlated with overall survival (Figure 6).

The ceRNA networks illustrated that PHLPP2 may be regulated by hsa-mir-32 and hsa-mir-141. Interestingly, PHLPP2 as well as hsa-mir-32 and hsa-mir-141 has been previously related to patient prognosis. We used the STRING protein database to analyze the protein–protein interactions of SERPINE1 and PHLPP2. The results revealed that SERPINE1 and PHLPP2 interact with V-akt murine thymoma viral oncogene homolog 1 (AKT1). Moreover, SERPINE1 can interact with several proteins including vascular endothelial growth factor A (VEGFA), vitronectin (VTN), transforming growth factor, beta 1 (TGFB1), plasminogen activator, urokinase (PLAU), plasminogen activator, urokinase receptor (PLAUR), plasminogen (PLG), and plasminogen activator, tissue (PLAT). Additionally, PHLPP2 can interact with AKT2 and AKT3 (Figure 7).

***Expression of IGF2-AS, POU6F2-AS2, and LINC00488 in cell lines***

To further confirm our *in silico* results, we performed RT-qPCR to detect the expression levels of IGF2-AS, POU6F2-AS2, and LINC00488 in CRC cell lines (HT29, LoVo, and SW480) and in a normal intestinal epithelial cell line (NCM460). We found that the expression of IGF2-AS and POU6F2-AS2 was significantly increased in CRC cell lines. Conversely, LINC00488 was downregulated in CRC cell lines compared with NCM460 (Figure 8).

DISCUSSION

The role of ceRNAs in tumorigenesis and development has remained controversial[21]. However, many studies have revealed the regulatory function of ceRNA networks in proliferation, invasion, metastasis, and epithelial–mesenchymal transition (EMT). This urgently requires the establishment of a comprehensive regulatory network based on a large sample size of whole genome sequences. By constructing regulatory networks, we can better clarify the role of ceRNAs and provide direction for further research.

In this study, we integrated lncRNA, miRNA, and mRNA high-throughput data from TCGA and constructed ceRNA networks. KEGG pathway analysis of DEmRNAs indicated that ceRNA networks may regulate CRC progression *via* multiple mechanisms. It is noteworthy that “Colorectal cancer” was the most significant pathway in which transcription factor 7 (TCF7), cyclin D1 (CCND1), and transforming growth factor, beta 2 (TGFB2) are involved. TCF7 is a critical signaling molecule in the WNT/β-catenin pathway, which belongs to the TCF/LEF1 family[22]. The WNT/β-catenin pathway is recognized as a key regulator in cancer by transcriptionally activating a variety of oncogenes including CCND1[23]. CCND1 has been validated as an oncogene in CRC, and it regulates the cell cycle transition from the G1 phase to the S phase[24]. Chen *et al*[25] showed that TGFB2 induces CRC migration, metastasis, and the EMT by promoting SNAIL and SLUG expression.

To identify novel prognosis-related biomarkers, we applied Kaplan–Meier curve analysis to identify DEGs in ceRNA networks that correlated with clinical features among CRC patients. Ultimately, we detected 3 DEmiRNAs (hsa-mir-32, hsa-mir-141, and hsa-mir-375), and 2 DEmRNAs (PHLPP2 and SERPINE1) that may be indicators of prognosis. Wu *et al*[26] showed that hsa-mir-32 promoted CRC growth, migration, and invasion by downregulating PTEN. Feng *et al*[27] revealed that hsa-mir-141 may act as a biomarker for the early detection of recurrence during CRC surveillance. Cui *et al*[28] found that hsa-mir-375 acts as an anti-oncogene through the inhibition of SP-1, BCL-2, and other EMT-associated genes. Increased SERPINE1 expression has been found in G3/G4 CRC cells, which may be a predictor of CRC invasiveness, progression, and overall survival[29]. PHLPP2, a protein phosphatase, is an isoform of PHLPP. PHLPP2 negatively regulates RAF/MEK/ERK signaling by directly inhibiting RAF1 activity to inhibit the progression of cancer[30]. Li *et al*[31] and Liao *et al*[32] reported that hsa-mir-938 and hsa-mir-224 repressed PHLPP2 expression in CRC. In the ceRNA networks identified here, our prediction showed that PHLPP2 is targeted by hsa-mir-141, hsa-mir-32, and hsa-mir-424. We noted that the hsa-mir-141/PHLPP2 and hsa-mir-32/PHLPP2 axis in ceRNA networks may be a diagnostic biomarker and a therapeutic target for the treatment of CRC.

In the present study, 1043 DElncRNAs were detected in 644 CRC tissues compared to 51 normal tissues. Among them, 3 DElncRNAs (IGF2-AS, POU6F2-AS2, and LINC00488) were related to the prognosis of CRC. The lncRNA IGF2-AS is an antisense lncRNA for IGF2, and has been validated to promote hepatitis C virus replication[33]. In our work, IGF2-AS may regulate target genes by competitive sponging against hsa-mir-150 and hsa-mir-193b. The lncRNA POU6F2-AS2 has been demonstrated to be overexpressed in esophageal squamous cell cancer, which can directly target the Ybx protein and protect cancer cells from ionizing radiation[34]. We predicted that hsa-mir-375 interacts with POU6F2-AS2, which is related with clinical prognosis. Additionally, hsa-mir-375 is related to overall survival. The POU6F2-AS2/hsa-mir-375 axis may be another crucial diagnosis-related target. However, little is known about LINC00488. To confirm the expression levels of these three lncRNAs, we performed RT-qPCR in CRC cell lines. The results were consistent with the *in silico* analysis results. Additionally, little is known about the functions of IGF2-AS, POU6F2-AS2, and LINC00488 in CRC. Thus, additional research is needed to explore the biological and molecular mechanisms of these DElncRNAs in CRC.

In summary, we analyzed the expression profiles of CRC samples from TCGA and constructed ceRNA networks of the DEGs. KEGG pathway analysis further confirmed the role of these ceRNA networks in the development of CRC. Moreover, we identified several DEGs that were related to clinical prognosis, and the expression of IGF2-AS, POU6F2-AS2, and LINC00488 was validated using RT-qPCR in cell lines. Our study deepens our understanding of ceRNA networks and provides potential therapeutic targets and prognosis-related biomarkers for further research.

**ARTICLE**

***Research background***

With the development of high-throughput technology, dysregulation of non-coding genes has been revealed in colorectal cancer (CRC). Furthermore, accumulating studies have demonstrated that long-noncoding RNAs (lncRNAs) function as competing endogenous RNAs (ceRNAs) to regulate oncogene and tumor suppressor gene expression by sponging microRNAs (miRNAs). In the present research, we constructed and analyzed the ceRNA networks and found the prognosis-related differentially expressed genes (DEGs) by bioinformatics analysis.

***Research motivation***

CRC is one of the most common malignancies in the world and the prognosis of patients in advanced stage remains poor. Therefore, specific biomarkers and novel therapeutic strategies are urgently required to improve the diagnosis and prognosis for CRC patients.

***Research objectives***

In our research, we aimed to construct ceRNA networks that include differentially expressed (DE)mRNAs, DElncRNAs, and DEmiRNAs based on co-expression database. Moreover, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis and protein-protein interactions network analysis were performed to confirm the importance of ceRNA networks in the development of CRC. Importantly, our study provides new potential lncRNA/miRNA/mRNA axis for future research and clinical practice.

***Research methods***

We obtained CRC tissue and normal tissue gene expression profiles from The Cancer Genome Atlas project. DEGs were identified by using the edgeR package in R software. Then, upregulated and downregulated miRNA-centered ceRNA networks were constructed by analyzing the DEGs using multiple bioinformatics approaches. The networks were visualized and mapped using Cytoscape software. DEmRNAs in the ceRNA networks were identified in KEGG pathways using KEGG Orthology Based Annotation System 3.0. Kaplan–Meier survival analysis was conducted for DEGs and real time quantitative polymerase chain reaction (RT-qPCR) was performed to verify the prognosis-associated DElncRNAs in CRC cell lines.

***Research results***

We constructed CRC ceRNA networks which included 81 DElncRNAs, 20 DEmiRNAs, and 54 DEmRNAs. KEGG pathway analysis indicated that nine pathways were related to cancer and the most significant pathway was “Colorectal cancer”. According to Kaplan–Meier curve analysis, the overall survival was positively associated with five DEGs (IGF2-AS, POU6F2-AS2, hsa-mir-32, hsa-mir-141, and SERPINE1) and it was negatively related to three DEGs (LINC00488, hsa-mir-375, and PHLPP2). The expression of prognosis-related DElncRNAs in CRC cell lines was consistent with the *in silico* results.

***Research conclusions***

In the present study, we provide a new pathway to construct ceRNA networks for cancer research and novel insights on non-coding RNAs in CRC. We identified and constructed the ceRNA networks of CRC in large cohorts. Enrichment analysis results verified the critical role of the ceRNA networks in CRC. Besides, multiple prognosis-related DEGs found in this research could be used as potential biomarkers and therapeutic targets.

***Research perspectives***

Further exploration of ceRNA networks provided a number of potential biomarkers and therapeutic targets for CRC. However, much more work is needed to reveal the function and mechanism of prognosis-related DEGs in the future.

REFERENCES

1 **Torre LA**, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. *CA Cancer J Clin* 2015; **65**: 87-108 [PMID: 25651787 DOI: 10.3322/caac.21262]

2 **Edwards BK**, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, Jemal A, Schymura MJ, Lansdorp-Vogelaar I, Seeff LC, van Ballegooijen M, Goede SL, Ries LA. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. *Cancer* 2010; **116**: 544-573 [PMID: 19998273 DOI: 10.1002/cncr.24760]

3 **Siegel RL**, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, Jemal A. Colorectal cancer statistics, 2017. *CA Cancer J Clin* 2017; **67**: 177-193 [PMID: 28248415 DOI: 10.3322/caac.21395]

4 **Brosnan CA**, Voinnet O. The long and the short of noncoding RNAs. *Curr Opin Cell Biol* 2009; **21**: 416-425 [PMID: 19447594 DOI: 10.1016/j.ceb.2009.04.001]

5 **Rigoutsos I**. New tricks for animal microRNAS: targeting of amino acid coding regions at conserved and nonconserved sites. *Cancer Res* 2009; **69**: 3245-3248 [PMID: 19351814 DOI: 10.1158/0008-5472.CAN-09-0352]

6 **Bartel DP**. MicroRNAs: target recognition and regulatory functions. *Cell* 2009; **136**: 215-233 [PMID: 19167326 DOI: 10.1016/j.cell.2009.01.002]

7 **Mattick JS**, Rinn JL. Discovery and annotation of long noncoding RNAs. *Nat Struct Mol Biol* 2015; **22**: 5-7 [PMID: 25565026 DOI: 10.1038/nsmb.2942]

8 **Salmena L**, Poliseno L, Tay Y, Kats L, Pandolfi PP. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? *Cell* 2011; **146**: 353-358 [PMID: 21802130 DOI: 10.1016/j.cell.2011.07.014]

9 **Chen DL**, Lu YX, Zhang JX, Wei XL, Wang F, Zeng ZL, Pan ZZ, Yuan YF, Wang FH, Pelicano H, Chiao PJ, Huang P, Xie D, Li YH, Ju HQ, Xu RH. Long non-coding RNA UICLM promotes colorectal cancer liver metastasis by acting as a ceRNA for microRNA-215 to regulate ZEB2 expression. *Theranostics* 2017; **7**: 4836-4849 [PMID: 29187907 DOI: 10.7150/thno.20942]

10 **Fang C**, Qiu S, Sun F, Li W, Wang Z, Yue B, Wu X, Yan D. Long non-coding RNA HNF1A-AS1 mediated repression of miR-34a/SIRT1/p53 feedback loop promotes the metastatic progression of colon cancer by functioning as a competing endogenous RNA. *Cancer Lett* 2017; **410**: 50-62 [PMID: 28943452 DOI: 10.1016/j.canlet.2017.09.012]

11 **Wang Y**, Liu Z, Yao B, Li Q, Wang L, Wang C, Dou C, Xu M, Liu Q, Tu K. Long non-coding RNA CASC2 suppresses epithelial-mesenchymal transition of hepatocellular carcinoma cells through CASC2/miR-367/FBXW7 axis. *Mol Cancer* 2017; **16**: 123 [PMID: 28716020 DOI: 10.1186/s12943-017-0702-z]

12 **Tay Y**, Rinn J, Pandolfi PP. The multilayered complexity of ceRNA crosstalk and competition. *Nature* 2014; **505**: 344-352 [PMID: 24429633 DOI: 10.1038/nature12986]

13 **Wang Z**, Jensen MA, Zenklusen JC. A Practical Guide to The Cancer Genome Atlas (TCGA). *Methods Mol Biol* 2016; **1418**: 111-141 [PMID: 27008012 DOI: 10.1007/978-1-4939-3578-9\_6]

14 **Jeggari A**, Marks DS, Larsson E. miRcode: a map of putative microRNA target sites in the long non-coding transcriptome. *Bioinformatics* 2012; **28**: 2062-2063 [PMID: 22718787 DOI: 10.1093/bioinformatics/bts344]

15 **Hsu SD**, Lin FM, Wu WY, Liang C, Huang WC, Chan WL, Tsai WT, Chen GZ, Lee CJ, Chiu CM, Chien CH, Wu MC, Huang CY, Tsou AP, Huang HD. miRTarBase: a database curates experimentally validated microRNA-target interactions. *Nucleic Acids Res* 2011; **39**: D163-D169 [PMID: 21071411 DOI: 10.1093/nar/gkq1107]

16 **Wong N**, Wang X. miRDB: an online resource for microRNA target prediction and functional annotations. *Nucleic Acids Res* 2015; **43**: D146-D152 [PMID: 25378301 DOI: 10.1093/nar/gku1104]

17 **Shannon P**, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res* 2003; **13**: 2498-2504 [PMID: 14597658 DOI: 10.1101/gr.1239303]

18 **Draghici S**, Khatri P, Tarca AL, Amin K, Done A, Voichita C, Georgescu C, Romero R. A systems biology approach for pathway level analysis. *Genome Res* 2007; **17**: 1537-1545 [PMID: 17785539 DOI: 10.1101/gr.6202607]

19 **Xie C**, Mao X, Huang J, Ding Y, Wu J, Dong S, Kong L, Gao G, Li CY, Wei L. KOBAS 2.0: a web server for annotation and identification of enriched pathways and diseases. *Nucleic Acids Res* 2011; **39**: W316-W322 [PMID: 21715386 DOI: 10.1093/nar/gkr483]

20 **Schmittgen TD**, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. *Nat Protoc* 2008; **3**: 1101-1108 [PMID: 18546601 DOI: 10.1038/nprot.2008.73]

21 **Thomson DW**, Dinger ME. Endogenous microRNA sponges: evidence and controversy. *Nat Rev Genet* 2016; **17**: 272-283 [PMID: 27040487 DOI: 10.1038/nrg.2016.20]

22 **Li Q**, Hua Y, Yang Y, He X, Zhu W, Wang J, Gan X. TCF7/TCF1 feedback controls osteocalcin signaling in brown adipocytes independent of canonical WNT/β-catenin pathway. *Mol Cell Biol* 2018 [PMID: 29358218 DOI: 10.1128/MCB.00562-17]

23 **Kafri P**, Hasenson SE, Kanter I, Sheinberger J, Kinor N, Yunger S, Shav-Tal Y. Quantifying β-catenin subcellular dynamics and cyclin D1 mRNA transcription during Wnt signaling in single living cells. *Elife* 2016; **5** [PMID: 27879202 DOI: 10.7554/eLife.16748]

24 **Lewis RC**, Bostick RM, Xie D, Deng Z, Wargovich MJ, Fina MF, Roufail WM, Geisinger KR. Polymorphism of the cyclin D1 gene, CCND1, and risk for incident sporadic colorectal adenomas. *Cancer Res* 2003; **63**: 8549-8553 [PMID: 14679024]

25 **Chen S**, Zhu J, Zuo S, Ma J, Zhang J, Chen G, Wang X, Pan Y, Liu Y, Wang P. 1,25(OH)2D3 attenuates TGF-β1/β2-induced increased migration and invasion via inhibiting epithelial-mesenchymal transition in colon cancer cells. *Biochem Biophys Res Commun* 2015; **468**: 130-135 [PMID: 26523511 DOI: 10.1016/j.bbrc.2015.10.146]

26 **Wu W**, Yang J, Feng X, Wang H, Ye S, Yang P, Tan W, Wei G, Zhou Y. MicroRNA-32 (miR-32) regulates phosphatase and tensin homologue (PTEN) expression and promotes growth, migration, and invasion in colorectal carcinoma cells. *Mol Cancer* 2013; **12**: 30 [PMID: 23617834 DOI: 10.1186/1476-4598-12-30]

27 **Feng L**, Ma H, Chang L, Zhou X, Wang N, Zhao L, Zuo J, Wang Y, Han J, Wang G. Role of microRNA-141 in colorectal cancer with lymph node metastasis. *Exp Ther Med* 2016; **12**: 3405-3410 [PMID: 27882171 DOI: 10.3892/etm.2016.3751]

28 **Cui F**, Wang S, Lao I, Zhou C, Kong H, Bayaxi N, Li J, Chen Q, Zhu T, Zhu H. miR-375 inhibits the invasion and metastasis of colorectal cancer via targeting SP1 and regulating EMT-associated genes. *Oncol Rep* 2016; **36**: 487-493 [PMID: 27222350 DOI: 10.3892/or.2016.4834]

29 **Mazzoccoli G**, Pazienza V, Panza A, Valvano MR, Benegiamo G, Vinciguerra M, Andriulli A, Piepoli A. ARNTL2 and SERPINE1: potential biomarkers for tumor aggressiveness in colorectal cancer. *J Cancer Res Clin Oncol* 2012; **138**: 501-511 [PMID: 22198637 DOI: 10.1007/s00432-011-1126-6]

30 **Li X**, Stevens PD, Liu J, Yang H, Wang W, Wang C, Zeng Z, Schmidt MD, Yang M, Lee EY, Gao T. PHLPP is a negative regulator of RAF1, which reduces colorectal cancer cell motility and prevents tumor progression in mice. *Gastroenterology* 2014; **146**: 1301-1312.e1-e10 [PMID: 24530606 DOI: 10.1053/j.gastro.2014.02.003]

31 **Li CF**, Li YC, Jin JP, Yan ZK, Li DD. miR-938 promotes colorectal cancer cell proliferation via targeting tumor suppressor PHLPP2. *Eur J Pharmacol* 2017; **807**: 168-173 [PMID: 28433657 DOI: 10.1016/j.ejphar.2017.04.023]

32 **Liao WT**, Li TT, Wang ZG, Wang SY, He MR, Ye YP, Qi L, Cui YM, Wu P, Jiao HL, Zhang C, Xie YJ, Wang JX, Ding YQ. microRNA-224 promotes cell proliferation and tumor growth in human colorectal cancer by repressing PHLPP1 and PHLPP2. *Clin Cancer Res* 2013; **19**: 4662-4672 [PMID: 23846336 DOI: 10.1158/1078-0432.CCR-13-0244]

33 **Xiong Y**, Jia M, Yuan J, Zhang C, Zhu Y, Kuang X, Lan L, Wang X. STAT3‑regulated long non‑coding RNAs lnc‑7SK and lnc‑IGF2‑AS promote hepatitis C virus replication. *Mol Med Rep* 2015; **12**: 6738-6744 [PMID: 26328522 DOI: 10.3892/mmr.2015.4278]

34 **Liu J**, Sun X, Zhu H, Qin Q, Yang X, Sun X. Long noncoding RNA POU6F2-AS2 is associated with oesophageal squamous cell carcinoma. *J Biochem* 2016; **160**: 195-204 [PMID: 27033944 DOI: 10.1093/jb/mvw025]

**P-Reviewer:** Bordonaro M, Langner C **S-Editor:** Wang XJ

**L-Editor:** Wang TQ **E-Editor:** Yin SY

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** China

**Peer-review report classification**


Grade A (Excellent): 0

Grade B (Very good): B, B


Grade C (Good): 0

Grade D (Fair): 0


Grade E (Poor): 0



**Figure 1 Heat map of** **differentially expressed long-noncoding RNAs (log2 FC > 5, *P* < 0.01).** The above horizontal axis shows clusters of samples. The left vertical axis shows clusters of differentially expressed long-noncoding RNAs (DElncRNAs) and right vertical axis represents lncRNA names. Red represents up-regulated genes and green represents down-regulated genes. The yellow color column represents colorectal cancer; the blue represents normal.

****

**Figure 2 Heat map of differentially expressed mRNAs (log2 FC > 5, *P* < 0.01).** The above horizontal axis shows clusters of samples. The left vertical axis shows clusters of differentially expressed mRNAs and right vertical axis represents mRNA names. Red represents up-regulated genes and green represents down-regulated genes. The yellow color column represents colorectal cancer; the blue represents normal.



**Figure 3 Heat map of differentially expressed microRNAs (log2 FC > 5, *P* < 0.01).** The above horizontal axis shows clusters of samples. The left vertical axis shows clusters of differentially expressed microRNAs (DEmiRNAs) and right vertical axis represents miRNA names. Red represents up-regulated genes and green represents down-regulated genes. The yellow color column represents colorectal cancer; the blue represents normal.



**Figure 4 Consensus target genes of differentially expressed microRNAs.** The target genes of the differentially expressed microRNAs were predicted with three online databases (TargetScan, miRDB, and miRTarBase).



**Figure 5 CeRNA networks of long-noncoding RNA-microRNA-mRNA in colorectal cancer.** The red represents the upregulated and the blue represents downregulated. Diamonds represent long-noncoding RNAs, balls represent mRNAs, and rectangles represent microRNAs.



**Figure 6 Kaplan-Meier curves for the** **3 long-noncoding RNAs, 3 microRNAs, and 2 mRNAs that are associated with overall survival in colorectal cancer.** The differentially expressed genes were ranked by the median of expression and then scored for each colorectal cancer patient in accordance with high or low-level expression (horizontal axis: overall survival time; vertical axis: survival function).



**Figure 7 Protein-protein interactions of PHLPP2 and SERPINE1.** The STRING protein database was utilized to analyze the protein-protein interactions of SERPINE1 and PHLPP2.



**Figure 8 IGF2-AS, POU6F2-AS2, and LINC00488 expression levels in colorectal cancer cell lines.** The expression of the three long-noncoding RNAs in HT29, LoVo, and SW480 and normal intestinal epithelial cell line NCM460 was detected by RT-qPCR and GAPDH was used as an internal control. a*P* < 0.01.

**Table 1 Putative differentially expressed long-noncoding RNAs that may target differentially expressed microRNAs**

|  |  |  |  |
| --- | --- | --- | --- |
| **DEmiRNA** | **DElncRNAs** | **DEmiRNA** | **DElncRNAs** |
| Hsa-mir-193b | IGF2-AS, H19, MIR31HG, WT1-AS, MUC19, UCA1, POU6F2-AS1, TSSC1-IT1, MRPL23-AS1, SPATA13-AS1, HOTAIR, WASIR2, DLX6-AS1, CRNDE, MALAT1, KCNQ1OT1 | Hsa-mir-182 | AC009336.1, C5orf64, AL360004.1, AC010336.2, SFTA1P, LINC00402, RBMS3-AS3, ADAMTS9-AS2, LIFR-AS1, FRMD6-AS2 |
| Hsa-mir-145 | SHANK2-AS3, WT1-AS, MUC19, ST7-AS2, MRPL23-AS1, FAM155A-IT1, FAM41C, MIR205HG, DLX6-AS1, OSBPL10-AS1, ERVH48-1, CRNDE, PVT1, LINC00491, MALAT1, NKX2-1-AS1, KCNQ1OT1, AL139147.1, ITCH-IT1, LINC00452 | Hsa-mir-106a | C20orf166-AS1, AC010336.2, HCG23, JAZF1-AS1, LINC00484, ADAMTS9-AS2, ARHGEF26-AS1, LIFR-AS1, LINC00461, LINC00507 |
| Hsa-mir-187 | SHANK2-AS3, MUC19, BTBD9-AS1, LINC00452, FAM41C, ATP11A-AS1, ERVH48-1, POU6F2-AS2 ARHGEF26-AS1, PVT1 | Hsa-mir-152 | C5orf64, AL360004.1, FAM95B1, LINC00484, ADAMTS9-AS2 |
| Hsa-mir-150 | IGF2-AS, C2orf48, SHANK2-AS3, C15orf54, HECW1-IT1, LINC00523, MUC19, ST7-OT4, CLDN10-AS1, TSSC1-IT1, MRPL23-AS1, BTBD9-AS1, LINC00355, LMO7-AS1, HOTAIR, MIR205HG, WASIR2, DLX6-AS1, LINC00460, LATS2-AS1, BOK-AS1, DSCAM-AS1, CAMTA1-IT1, PVT1, LINC00491, HULC, MALAT1, C8orf49, KCNQ1OT1, AL139147.1, AL391421.1 | Hsa-mir-338 | GRIK1-AS1, C5orf64, AC010336.2, LINC00473, FAM95B1, AC110491.1, LINC00402, LINC00484, ADAMTS9-AS2, LINC00461, FRMD6-AS2, PWRN1 |
| Hsa-mir-375 | C15orf54, C17orf77, WT1-AS, MUC19, STEAP2-AS1, LMO7-AS1, HOTAIR, OSBPL10-AS1, POU6F2-AS2 MACROD2-AS1, DLEU7-AS1, MALAT1, C8orf49, KCNQ1OT1, AL139147.1 | Hsa-mir-17 | C20orf166-AS1, C5orf64, AC010336.2, HCG23, JAZF1-AS1, LINC00402, ARHGEF26-AS1 |
| Hsa-mir-183 | C20orf166-AS1, AL360004.1, FAM95B1, CHL1-AS2, ADAMTS9-AS2, LINC00507 | Hsa-mir-424 | C5orf64, AL360004.1, LINC00473, LINC00092, SFTA1P, LINC00484, LINC00461, PWRN1 |
| Hsa-mir-98 | LINC00488, FAM95B1, AC110491.1, JAZF1-AS1, LINC00484, ADAMTS9-AS2, PWRN1 | Hsa-mir-21 | C5orf64, AL360004.1, LINC00488, JAZF1-AS1, ADAMTS9-AS1, ARHGEF26-AS1, PWRN1 |
| Hsa-mir-144 | AL360004.1, AC010336.2, LINC00488, ADAMTS9-AS1, ADAMTS9-AS2, LIFR-AS1, LINC00461, PWRN1 | Hsa-mir-454 | C20orf166-AS1, ADAMTS9-AS1, ADAMTS9-AS2 |
| Hsa-mir-32 | JAZF1-AS1, LINC00484, ADAMTS9-AS2, ARHGEF26-AS1 | Hsa-mir-141 | C5orf64, AC010336.2, FAM95B1, AC110491.1, LINC00402, LINC00484, ADAMTS9-AS2, ARHGEF26-AS1, LINC00461 |
| Hsa-mir-206 | LINC00488, FAM95B1, LINC00092, SFTA1P, LINC00163, LINC00484, AL138995.1, LIFR-AS1, FRMD6-AS2 | Hsa-mir-372 | C20orf166-AS1, AC010336.2, HCG23, JAZF1-AS1, LINC00484, ADAMTS9-AS2, ARHGEF26-AS1, LIFR-AS1, LINC00461 |

DElncRNAs: Differentially expressed long-noncoding RNAs; DEmiRNAs: Differentially expressed microRNAs.

**Table 2 Putative differentially expressed microRNAs that may target differentially expressed mRNAs**

|  |  |
| --- | --- |
| DEmiRNA | DEmRNAs |
| Hsa-mir-193b | PLAU, PMAIP1, TCF7, CCND1, SHMT2 |
| Hsa-mir-145 | SERPINE1, SOX2, MUC1, YES1 |
| Hsa-mir-187 | LYN, RNPS1, MYLIP |
| Hsa-mir-375 | TRIM66, USP1, TGFB2, COL12A1, CBX3, SP1 |
| Hsa-mir-150 | CBL, ZEB1, HILPDA, SLC7A11, DACH1, EREG, IGF2BP3, KIAA1549, MYB |
| Hsa-mir-183 | KIF5C |
| Hsa-mir-98 | HAND1 |
| Hsa-mir-144 | CRIK3 |
| Hsa-mir-182 | CHL1, FOXF2, TCEAL7, NPTX1 |
| Hsa-mir-152 | NPTX1, BMP3, KLF4 |
| Hsa-mir-454 | RBM20, CFL2 |
| Hsa-mir-106a | CFL2, FAM129A, CADM2 |
| Hsa-mir-372 | TMEM100, CADM2, |
| Hsa-mir-17 | SLC16A9, CYBRD1, KLF4, CADM2, FAM129A |
| Hsa-mir-424 | TPM2, TMEM100 |
| Hsa-mir-21 | ATP2B4, EDIL3, OSR1 |
| Hsa-mir-32 | UGP2, PBLD, PHLPP2, ATP2B4 |
| Hsa-mir-141 | ELAVL4, EPHA7, PHLPP2 |
| Hsa-mir-338 | NOVA1 |
| Hsa-mir-206 | SFRP1 |

**Table 3 Top 10 Kyoto Encyclopedia of Genes and Genomes pathways enriched by the differentially expressed mRNAs involved in competing endogenous RNAs networks**

|  |  |  |  |
| --- | --- | --- | --- |
| **Pathway ID** | **Description** | ***P*-value** | **Gene name** |
| hsa05210 | Colorectal cancer | 8.18E-05 | TCF7, CCND1, TGFB2 |
| hsa04115 | p53 signaling pathway | 1.11E-04 | SERPINE1, CCND1 |
| hsa05220 | Chronic myeloid leukemia | 1.30E-04 | CCND1, CBL, TGFB2 |
| hsa05205 | Proteoglycans in cancer | 1.52E-04 | CCND1, CBL, TGFB2, PLAU |
| hsa05206 | MicroRNAs in cancer | 6.20E-04 | ZEB1, CCND1, PLAU, TGFB2 |
| hsa05216 | Thyroid cancer | 7.31E-04 | TCF7, CCND1 |
| hsa04550 | Signaling pathways regulating pluripotency of stem cells | 8.67E-04 | SOX2, KLF4, HAND1 |
| hsa04310 | Wnt signaling pathway | 8.84E-04 | TCF7, CCND1, SFRP1 |
| hsa05202 | Transcriptional misregulation in cancer | 1.69E-03 | SP1, PLAU, ZEB1 |
| hsa05200 | Pathways in cancer | 1.74E-03 | TCF7, CCND1, CBL, TGFB2 |